TransMedics Group (NASDAQ:TMDX) Reaches New 12-Month Low – Time to Sell?

TransMedics Group, Inc. (NASDAQ:TMDX)’s share price hit a new 52-week low during trading on Thursday . The company traded as low as $60.40 and last traded at $60.88, with a volume of 1588704 shares. The stock had previously closed at $65.71.

Analysts Set New Price Targets

Several equities analysts have weighed in on TMDX shares. Piper Sandler cut their target price on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. TD Cowen cut their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday. Robert W. Baird cut their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Finally, Canaccord Genuity Group decreased their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Stock Performance

The stock’s 50 day moving average is $88.42 and its two-hundred day moving average is $128.82. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of 65.64 and a beta of 2.06. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same quarter last year, the business earned ($0.12) earnings per share. TransMedics Group’s revenue for the quarter was up 63.7% on a year-over-year basis. Analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In other news, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total transaction of $438,493.92. Following the sale, the insider now owns 20,843 shares in the company, valued at $3,089,766.32. This represents a 12.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the transaction, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 19,417 shares of company stock worth $2,240,738 in the last three months. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently modified their holdings of the company. Amalgamated Bank increased its position in TransMedics Group by 6.7% during the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after buying an additional 70 shares during the last quarter. Harbour Capital Advisors LLC increased its holdings in shares of TransMedics Group by 1.7% during the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after acquiring an additional 81 shares during the last quarter. Signaturefd LLC raised its stake in TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after acquiring an additional 93 shares during the period. Arizona State Retirement System boosted its position in TransMedics Group by 2.1% during the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock worth $1,379,000 after purchasing an additional 186 shares during the period. Finally, Venturi Wealth Management LLC increased its holdings in shares of TransMedics Group by 33.7% in the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after purchasing an additional 219 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.